Supplementary Figure S5. Cell proliferation inhibition of cetuximab, FASN inhibitor (EGCG or C75) and the combination. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer

Autor:	Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
Rok vydání:	2023
Popis:	(A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with doxorubicin (50-100-150nM) and C75 (20µM for HCC, HCCDXR; 40µM for 231, 231DXR) or the combination for 48h. (C) 231 and 231DXR and (D) HCC and HCCDXR cells were treated with doxorubicin (50-100-150nM), EGCG (100µM for 231, 231DXR; 120µM for HCC, HCCDXR) or the combination of both for 48h. Results shown are mean {plus minus} SEM. *(p < 0.05), **(p < 0.01) and ***(p < 0.001) indicate levels of statistically significance.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::443258cd2e2ece25708066dba734bd8f https://doi.org/10.1158/1078-0432.22462599 Zobrazit plný text záznamu